Swiss pharma acquires Gameto for $1.38B in fertility biotech deal

Argentine-Spanish businessman Martín Varsavsky announced the sale of Gameto, a fertility-focused biotech firm, to a Swiss pharmaceutical company for US$1,382.5 million. The deal signals continued consolidation in the reproductive medicine sector, though the buyer's identity and strategic rationale remain undisclosed. This transaction is notable for its size and cross-border nature, potentially impacting the fertility treatment market.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works